Predicting the Development of Gastric Neoplasms in a Healthcare Cohort by Combining Helicobacter pylori Antibodies and Serum Pepsinogen: A 5-Year Longitudinal Study

Table 1

Baseline characteristics of subjects according to the group.

	Total	Group A	Group B	Group C	Group D	value
Number of subjects (%)	3297 (100%)	1239 (37.6%)	1484 (45.0%)	536 (16.3%)	38 (1.2%)
H. pylori Ab		Negative	Positive	Positive	Negative
Pepsinogen		Normal	Normal	Atrophic	Atrophic
Age (years)^a	51.3 ± 9.4	50.0 ± 9.6	51.0 ± 8.8	55.1 ± 9.4	53.3 ± 8.3	0.039
Male sex (%)	2326 (70.5%)	854 (68.9%)	1096 (73.9%)	353 (65.9%)	22 (57.9%)	<0.001
Pepsinogen I (ng/mL)^a	57.8 ± 29.9	49.9 ± 25.5	71.0 ± 31.7	42.5 ± 16.3	19.3 ± 12.2	<0.001
Pepsinogen II (ng/mL)^a	14.7 ± 9.1	8.9 ± 4.8	18.0 ± 10.0	19.3 ± 7.3	11.0 ± 4.9	0.013
Pepsinogen I/II ratio^a	4.5 ± 1.8	5.8 ± 1.4	4.3 ± 1.3	2.2 ± 0.6	1.8 ± 0.9	<0.001
Follow-up duration (years)^a	5.6 ± 2.0	5.6 ± 1.9	5.5 ± 2.0	5.5 ± 2.0	5.4 ± 2.0	0.404
Follow-up duration (months (median, range))	80 (12–104)	81 (12–103)	79 (12–104)	79 (12–104)	77 (22–102)	0.325

^aMean ± SD.